UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [√] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OCTOBER 31, 2016 Commission file number: 333-195397 OMNI HEALTH, INC. (Exact name of registrant as specified in its charter)
NEVADA	46-4597341
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
5966 W 16th Avenue, Hialeah, Florida	33012
(Address of principal executive offices)	(Zip Code)
Registrant’s telephone number, including area code	800-709-8742
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [√] Yes [ ] No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [ ] Yes [√] No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ]	Smaller reporting company [√]
(Do not check if smaller reporting company)

UNITED STATES

~~Omni~~SECURITIES AND ~~Health,~~EXCHANGE ~~Inc. TABLE OF CONTENTS~~COMMISSION

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements	3
Condensed Consolidated Balance Sheets as of October 31, 2016 (unaudited) and April 30, 2016	4
Condensed Consolidated Statements of Operations for the three months ended October 31, 2016 and 2015 (Unaudited)	5
Condensed Consolidated Statements of Cash Flows for the three months ended October 31, 2016 and 2015(Unaudited)	6
Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3. Quantitative and Qualitative Disclosures about Market Risk	20
Item 4. Controls and Procedures	20
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	21
Item 1A. Risk Factors	21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3. Defaults Upon Senior Securities	21
Item 4. Mine Safety Disclosures	21
Item 5. Other Information	21
Item 6. Exhibits	21
SIGNATURES	22
2

Washington, D.C. 20549

PART I – FINANCIAL INFORMATION Item 1. Financial Statements Interim Condensed Financial Statements and Notes to Interim Financial Statements General The accompanying unaudited condensed interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company's annual report on Form 10-K for the year ended April 30, 2016. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three months and six months ended October 31, 2016 are not necessarily indicative of the results that can be expected for the year ending April 30, 2017. 3

Omni Health, Inc. and Subsidiaries Consolidated Balance Sheets ASSETS October 31, April 30, 2016 2016 (~~unaudited)~~ Mark Current Assets Cash and cash equivalents $ 21,858 $ 21,834 Accounts Receivable, Net 785,780 4,708 Inventory 267,019 26,641 Other receivables and Prepaid Expenses 150,000 3,300 Total Current Assets 1,224,657 56,483 Property, Plant and Equipment, Net 311,240 1,601 Cost Basis Investment 3,430,973 - Total Assets $ 4,966,870 $ 58,084 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Notes Payable, Current Portion $ 841,309 $ - Accounts Payable and Accrued Expenses 228,038 2,000 Due to mCig, Inc. - 186,276 Due to Related Party - 2,000 Total Current Liabilities 1,069,347 190,276 Noncurrent Liabilities Due to Related Party 601,527 - Total Liabilities 1,670,874 190,276 Stockholders' Equity Common Stock, $0.0001 par value, voting; 2,000,000,000 shares authorized; 1,148,328,741 and 554,551,683 shares issued, and outstanding, as of October 31, 2016 and April 30, 2016, respectively. 114,723 55,455 Treasury Stock (1,052,250One) - Additional Paid In Capital 3,817,791 386,450 Accumulated Deficit 415,732 (574,097) Total Stockholders' Equity 3,295,996 (132,192) Total Liabilities and Stockholders' Equity $ 4,966,870 $ 58,084 See accompanying notes to unaudited consolidated financial statements. 4

[√] ~~Omni~~QUARTERLY ~~Health,~~REPORT ~~Inc. and~~PURSUANT ~~Subsidiaries Consolidated~~TO ~~Statements~~SECTION of Operations (Unaudited) Three Months Ended October 31, Six Months Ended October 31, 2016 2015 2016 2015 Sales $ 1,285,503 $ 11,707 $ 1,799,950 $ 78,743 Total Cost of Sales (904,692) (3,616) (1,293,568) (48,082) Gross Profit 380,811 8,091 506,382 30,661 Selling, general, and administrative 136,079 61,079 200,871 102,795 Professional fees - 13~~,750~~ ~~1,075~~OR 13,750 Payroll 69,874 - 114,752 - Consulting fees 131,738 - 170,670 - Amortization and Depreciation 7,653 367 7,653 733 Total Operating Expenses 345,344 75,196 495,021 117,278 Net Income15(~~Loss~~d) ~~from~~OF ~~operations 35,467~~THE ~~(67,105) 11,361~~SECURITIES ~~(86,617) Other~~EXCHANGE ~~(Expense) (73,772) -~~ACT ~~(102,705) -~~OF Net (Loss) from Continuing Operations (38,305) (67,105) (91,344) (86,617) Net Income from Discontinued Operations - - 1,081,173 - Net Income (Loss) $ (38,305) $ (67,105) $ 989,829 $ (86,617) Basic and Diluted (Loss) Per Share: Income(Loss) per share from Continuing Operations $ (0.00) $ (0.00) $ (0.00) $ (0.00) Income(Loss) Per Share $ (0.00) $ (0.00) $ 0.00 $ (0.00) Weighted Average Shares Outstanding - Basic and Diluted 854,959,292 503,232,826 854,959,292 501,683,913 See accompanying notes to unaudited consolidated financial statements. 5 1934

Omni Health, Inc.
and Subsidiaries
Statements of Cash Flows
(Unaudited)
				For the Six Months Ended October 31,
				2016	2015
Cash Flows From Operating Activities:
Net (Loss)				$ 989,829
Adjustments to Reconcile Net Loss to Net
	Cash Provided By (Used In) Operating Activities:
		Depreciation and Amortization		7,653	734
		Common stock issued for services		-	54,300
	Decrease (Increase) in:
		Accounts Receivable, Net		(781,072)	(7)
		Inventories		(240,378)	6,637
		Other receivables and Prepaid Expenses		(146,700)	-
		Accounts Payable, Accrued Expenses and Taxes Payable		226,038	(1,500)
		Deferred Revenue		-	(35,700)
	Total Adjustment to reconcile Net Income to Net Cash			(934,459)	24,464
			Net Cash Provided In Operating Activities	55,370	(62,153)
Cash Flows From Investing Activities:
	Increase (Decrease) in:
		Net cash received from acquisition		(3,430,973)	-
		Acquisition of property, plant and equipment		(317,292)	-
			Net cash received in investing activities	(3,748,265)	-
Cash Flows From Financing Activities:
		Proceeds from issuance of common stock		2,438,359
		Notes Payable, Net		859,836	-
		Proceeds from (Repayment of) loan with related parties		394,724	(4,996)
			Net Cash Provided By (Used in) Financing Activities	3,692,919	(4,996)
Net Change in Cash				24	(67,149)
Cash at Beginning of Period				21,834	70,516
Cash at End of Period				$ 21,858	$ 3,367
Supplemental Disclosure of Cash Flows Information:
		Cash paid for interest		$ -	$ -
		Cash paid for income taxes		$ -	$ -
See accompanying notes to unaudited consolidated financial statements. 6

For the quarterly period ended January 31, 2017

~~OMNI~~[ ] ~~HEALTH,~~TRANSITION ~~INC.~~REPORT ~~Notes~~PURSUANT toTO ~~Condensed~~SECTION ~~Consolidated~~13 ~~Financial~~OR ~~Statements~~ 15(~~Unaudited~~d) ~~Note~~OF 1THE –SECURITIES ~~Organization~~EXCHANGE ~~and~~ACT ~~Basis~~OF of Presentation The accompanying audited financial statements of Omni Health, Inc., formerly known as VitaCig, Inc., (the “Company”, “we”, “our”), have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (“SEC”). Description of Business We were incorporated in Nevada on January 22, 2014. We began as a technology company that was engaged in the manufacturing and retailing of nicotine-free Electronic Cigarettes (“eCigs”) that are pre-packaged with vitamins, nutrients, and generic pharmaceuticals. The Company was originally formed as a wholly-owned subsidiary of mCig, Inc. On February 24, 2014 the company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement VitaCig, Inc. accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO and $500 in cash as contribution in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of the Company. On November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc. (the “Spin-off”) (See Note 9: Stockholders’ Equity of the Audited Financial Statement). On June 17, 2016 VitaCig acquired Malecon Pharmacy, Inc., in a Stock Exchange Agreement. VitaCig issued LX Retail Group, LLC 575,000,000 common shares of stock in exchange for 100% of the stock of Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., operates as a subsidiary of VitaCig, Inc. Malecon Pharmacy is a pharmacy that operates in Hialeah, Florida since 1974. On June 22, 2016 VitaCig sold its eCig business element to mCig, Inc., in exchange for the return to treasury stock 172,500,000 shares of VitaCig stock and the reduction of the outstanding amount owed by Vitacig, Inc., to mCig, Inc., in the amount equal to reducing the outstanding balance to $95,000. As a result of this transaction, VitaCig, Inc., became a holding company in which it has one wholly owned subsidiary, Malecon Pharmacy, Inc. On September 9, 2016 the company changed its name to Omni Health, Inc. The Company currently maintains its corporate office in Miami Beach, Florida. Note 2 – Summary of Significant Accounting Policies The principal accounting policies are set out below, these policies have been consistently applied to the period presented, unless otherwise stated: Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include: sales returns and other allowances; allowance for doubtful accounts; valuation of inventory; valuation and recoverability of long-lived assets; property and equipment; contingencies; and income taxes. On a regular basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Inventory Prior to the acquisition of Malecon Pharmacy and the discontinued operations, inventory consisted of finished product, e-Cig products valued at the lower of cost and net realizable value under the first-in, first-out method of costing. Upon the acquisition of Malecon Pharmacy, the inventory consisted of prescription drugs, non-prescription drugs and retail merchandise. The Company continues to value its inventory at the lower of cost and net realizable value under the first-in, first-out method of costing. 71934

Item	October 31, 2016	April 30, 2016
Prescription Drugs	$ 119,201	$ -
Non-prescription Drugs	40,559	-
Retail Merchandise	107,259	-
Finished Goods	-	26,641
Total Inventory	$ 267,019	$ 26,641

For the transition period from _______________ to _______________.

~~Accounts~~Commission file ~~Receivable~~number: The Company's accounts receivable is primarily from its contracts associated with healthcare insurance companies. Under various agreements, the Company maintains receivables with 17 companies with accounts ranging from 30333-90 days. While the company attempts to collect on all outstanding balances owed, the financial statements do not account for any outstanding receivables beyond 90 days. All receivables beyond 90 days are written off as a drawn down from revenue. Should the company collect at a later date, which it intends to do, the Company reinstates the revenue during the quarter in which it is paid. Due to the nature of these funds, the Company expects these receivables to be fully collectible and therefore has not estimated an allowance for doubtful accounts for the period. The Company did not report any accounts receivable from any of its retail customers. The following table reflects the accounts receivables as of October 31, 2016.195397

		Amount
0-30 days		$ 254,282
31-60 days		256,408
61-90 days		275,090
Total		$ 785,780

OMNI HEALTH, INC.

Intangible Assets The Company’s intangible assets consist primarily of certain website development costs and are amortized over its estimated useful life of three years. Revenue Recognition Pharmacy Services. We sells prescription drugs directly through our mail service pharmacies, home delivery, and through our retail pharmacy. We recognize revenues from prescription drugs sold by our mail service and home delivery and the retail pharmacy through contracts where we are the principal using the gross method at the contract prices negotiated with our customers. Revenue from Pharmacy Services includes: (i)Exact name ~~the portion~~ of ~~the~~registrant ~~price~~as ~~the~~specified ~~customer pays directly to us, net of any volume-related or other discounts paid back to the customer, (ii) the portion of the price paid to us~~ in a national retail pharmacy network through the customers insurance plan, and (iii) administrative payments from national retail pharmacy network contracts for incentives and initiatives. SEC Staff Accounting Bulletin 104, “Revenue Recognition, corrected copy” ( “SAB 104”) provides the general criteria for the timing aspect of revenue recognition, including consideration of whether: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable and (iv) collectability is reasonably assured. The Company has established the following revenue recognition policies in accordance with SAB 104: · Revenues generated from prescription drugs sold by mail service pharmacies are recognized when the prescription is shipped. At the time of shipment, the Company has performed substantially all of its obligations under its customer contracts and does not experience a significant level of reshipments. · Revenues generated from prescription drugs sold through national retail pharmacy network and associated administrative fees are recognized at the point-of-sale, which is when the claim is adjudicated by the online claims processing system. We determine whether we are the principal or agent for our national retail pharmacy network transactions using the indicators set forth in Emerging Issues Task Force (“EITF”charter) Issue No. 99-19, “Reporting Revenue Gross as a Principal versus Net as an Agent” on a contract by contract basis. In all of our current contracts, we have determined we are the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in establishing the price, changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications and (v) having credit risk. Responsibilities under our customer contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the physician prior to dispensing, suggesting clinically appropriate generic alternatives where appropriate and approving the prescription for dispensing. Although we do not have credit risk with respect to Retail Co-Payments, management believes that all of the other indicators of gross revenue reporting are present. 8

Drug Discounts ~ We deduct from our revenues any discounts paid to our customers as required by EITF No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products)” (“EITF 01-9”). Retail Pharmacy Segment ~ We recognize revenue from the sale of merchandise (other than prescription drugs) at the time the merchandise is purchased by the retail customer. Revenue from the sale of prescription drugs is recognized at the time the prescription is filled, which is or approximates when the retail customer picks up the prescription. Customer returns are not material. Revenue generated from the performance of services is recognized at the time the services are performed. Cost of Goods Sold The Company recognizes the direct cost of purchasing product for sale, including freight-in and packaging, as cost of goods sold in the accompanying income statement. Financial Instruments The carrying amounts reflected in the balance sheets for cash and due to related parties approximate the respective fair values due to the short maturities of these items. The Company does not hold any investments that are available-for-sale. As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1—Valuations based on quoted prices for identical assets and liabilities in active markets. Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3—Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. Income Taxes Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Basic and Diluted Net Income (Loss) Per Share The Company follows ASC Topic 260 to account for earnings (loss) per share. Basic earnings (loss) per share (“EPS”) calculations are determined by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the three months. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. There is no potential dilutive security as of October 31, 2016 or 2015. Concentration of Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash and trade receivables. Concentrations of credit risk with respect to trade receivables are limited due to the clients that comprise our customer base and their dispersion across different business and geographic areas. We estimate and maintain an allowance for potentially uncollectible accounts and such estimates have historically been within management's expectations. 9

Nevada

(State or other jurisdiction of

incorporation or organization)

46-4597341

(I.R.S. Employer

Identification No.)

400 W 41st Street, Suite 506,

Miami Beach, Florida

(Address of principal executive offices)

33140

(Zip Code)

(800) 709-8742

Registrant’s telephone number, including area code

VitaCig, Inc.

433 North Camden Drive, 6th Floor,

Beverly Hills, CA 90210

(Former name and address, if changed since last report)

~~Our cash balances are maintained in accounts held~~ Indicate by ~~major~~check ~~banks~~mark ~~and~~whether ~~financial institutions located in~~ the ~~United~~registrant ~~States.~~(1) ~~The~~has ~~Company~~filed ~~may occasionally maintain amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining~~ all ~~deposits~~reports inrequired ~~high~~to quality financial institutions. The Company had no deposits in excess of federally insured limits at October 31, 2016 and April 30, 2015. Impairment of Long-lived Assets The Company accounts for long-lived assets in accordance with the provisions of FASB Topic 360, “Accounting for the Impairment of Long-Lived Assets”. This statement requires that long-lived assets and certain identifiable intangibles be ~~reviewed~~filed ~~for~~by ~~impairment~~Section ~~whenever~~13 ~~events~~ or ~~changes~~15(d) ~~in circumstances indicate that the carrying amount~~ of ~~an asset may not be recoverable. An impairment loss would be recognized when~~ the ~~estimated~~Securities ~~future~~Exchange Act ~~cash flows from the use~~ of ~~the~~1934 ~~asset are less than the carrying amount of that asset. No impairments were recorded~~ during the ~~periods~~preceding ~~ended~~12 October 31, 2016 and 2015. Warranties Warranty reserves include management’s best estimate of the projected costs to repair or to replace any items under warranty, based on actual warranty experience as it becomes available and other known factors that may impact the Company’s evaluation of historical data. The Company did not have any significant warranty expenses to report for the three months ended October 31, 2016. Based on these actual expenses, the warranty reserve, as estimated by management as of October 31, 2016 was at $0. Any adjustments to warranty reserves are to be recorded in cost of sales. Recent Accounting Pronouncements The Company evaluated all recent accounting pronouncements issued and determined that the adoption of these pronouncements would not have a material effect on the financial position, results of operations, or cash flows of the Company. In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Components of an Entity, which updates the definition of discontinued operations. Going forward, only those disposals of components of an entity that represent a strategic shift that has (or will have) a major effect on an entity's operations and financial results will be reported as discontinued operations in the financial statements. Previously, a component of an entity that is a reportable segment, an operating segment, a reporting unit, a subsidiary, or an asset group was eligible for ~~discontinued~~such ~~operations~~shorter ~~presentation.~~period ~~Additionally, the condition~~ that the ~~entity~~registrant ~~not~~was have any significant continuing involvement in the operations of the component after the disposal transaction has been removed. The effective date for the revised standard is for applicable transactions that occur within annual periods beginning on or after December 15, 2014. We do not expect the guidance to have a material impact on the Company. In July 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-11 "Simplifying the Measurement of Inventory"; guidance which requires inventory within the scope of the standard to be measured at the lower of cost and net realizable value. Previous guidance required ~~inventory~~ to befile ~~measured~~such ~~at the lower of cost or market (where market was defined as replacement cost~~reports), ~~with a ceiling of net realizable value~~ and ~~floor of net realizable value less a normal profit margin~~(2). The updated guidance is effective for interim and annual reporting periods beginning after December 15, 2016, with early adoption permitted. There were various other updates recently issued, none of which are expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Note 3 - Going Concern The Company's financial statements are prepared using generally accepted accounting principles, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. Because the business is new and has ~~a limited history and relatively few sales, no certainty of continuation can be stated. The accompanying financial statements for the six months and three months ended October 31, 2016 and 2015 have~~ been ~~prepared~~subject assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.. The Company has suffered losses from operations, which raises substantial doubt about its ability to ~~continue~~such asfiling ~~a going concern. Management is taking steps to raise additional funds to address its operating and financial cash~~ requirements to continue operations in the next twelve months. Management has devoted a significant amount of time in the raising of capital from additional debt and equity financing. However, the Company’s ability to continue as a going concern is dependent upon raising additional funds through debt and equity financing and generating revenue. There are no assurances the Company will receive the necessary funding or generate revenue necessary to fund operations. The financial statements contain no adjustments for the ~~outcome~~past of90 ~~this uncertainty~~days. ~~Note~~Yes 4[√] -No ~~Intangible~~[ ~~Assets:~~]

		As of
		April 30, 2016
	WeightedAverageUseful Life(in Years)	Gross Carrying Amount	Accumulated Amortization	Net CarryingAmount
		$	$	$
Finite lived intangible assets
Internet website	3	4,400	(2,799)	1,601
Total identifiable intangible assets		4,400	(2,799)	1,601

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [√]

		As of
		June 22, 2016
	WeightedAverageUseful Life(in Years)	Gross Carrying Amount	Accumulated Amortization	Net CarryingAmount
		$	$	$
Finite lived intangible assets
Internet website	3	4,400	(3,057)	1,343
Total identifiable intangible assets		4,400	(3,057)	1,343

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

[ ]

Accelerated filer

[ ]

Non-accelerated filer

(Do not check if smaller reporting company)

[ ]

Smaller reporting company

[√]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [√]

As of March 4, 2017, the Company had 975,828,741 shares of common stock, $0.0001 par value outstanding.

Transitional Small Business Disclosure Format Yes [ ] No [√]

Table of Contents

Omni Health, Inc. TABLE OF CONTENTS
	PART I. FINANCIAL INFORMATION
	Item 1. Financial Statements	3
	Condensed Consolidated Balance Sheets as of January 31, 2017 (unaudited) and April 30, 2016	4
	Condensed Consolidated Statements of Operations for the three months and nine months ended January 31, 2017 and 2016 (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended January 31, 2017 and 2016 (Unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
	Item 3. Quantitative and Qualitative Disclosures about Market Risk	24
	Item 4. Controls and Procedures	24
	PART II. OTHER INFORMATION
	Item 1. Legal Proceedings	25
	Item 1A. Risk Factors	25
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	25
	Item 3. Defaults Upon Senior Securities	26
	Item 4. Mine Safety Disclosures	26
	Item 5. Other Information	26
	Item 6. Exhibits	26
	SIGNATURES	26

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Interim Condensed Financial Statements and Notes to Interim Financial Statements

General

The accompanying unaudited condensed interim financial statements have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ deficit in conformity with generally accepted accounting principles. Except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements included in the Company’s annual report on Form 10-K for the year ended April 30, 2017. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three months and nine months ended January 31, 2017 are not necessarily indicative of the results that can be expected for the year ending April 30, 2017.

Table of Contents

Omni Health, Inc.

and SUBSIDIARIES
Consolidated Balance Sheets

		(unaudited) January 31,			April 30,
		2017			2016
ASSETS
Current Assets
Cash and cash equivalents	$	7,649		$	21,834
Accounts Receivable, Net		839,393			4,708
Inventory		286,154			26,641
Other Receivables and Prepaid Expenses		150,000			3,300
Total Current Assets		1,283,196			56,483
Property, Plant and Equipment, Net		301,169			1,601
Cost Basis Investment		3,430,973			—
Total Assets	$	5,015,338		$	58,084
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Notes Payable, Current Portion	$	901,017		$	—
Accounts Payable and Accrued Expenses		295,706			2,000
Due to mCig, Inc.		—			186,276
Due to Related Party		—			2,000
Total Current Liabilities		1,196,723			190,276
Noncurrent Liabilities
Bank loans		23,968
Due to Related Party		573,000			—
Total Liabilities		1,793,691			190,276
Stockholders' Equity
Common Stock, $0.0001 par value, voting; 2,000,000,000 shares		97,583			55,455
authorized; 975,828,741 and 554,551,683 shares issued, and
outstanding, as of January 31, 2017 and April 30, 2016
Treasury Stock		(1,052,250	)		—
Shares issued at spinoff, discount from par value		—			(49,514	)
Additional Paid In Capital		3,834,931			435,964
Accumulated Deficit		341,383			(574,097	)
Total Stockholders' Equity		3,221,647			(132,192	)
Total Liabilities and Stockholders' Equity	$	5,015,338		$	58,084

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

Omni Health, Inc.
and SUBSIDIARIES
Consolidated Statements of Operations
(unaudited)

	Three Months Ended January 31,						Nine Months Ended January 31,
	2017			2016			2017			2016
Sales	$	1,470,844		$	39,110		$	3,270,794		$	117,853
Total Cost of Sales		1,072,701			37,473			2,366,269			85,555
Gross Profit		398,143			1,637			904,525			32,298
Selling, general, and administrative		72,973			20,310			275,843			123,105
Professional fees		16,000			5,000			21,075			18,750
Payroll		98,860			—			187,080			—
Consulting fees		249,742			—			424,945			—
Amortization and Depreciation		10,071			367			17,724			1,100
Total Operating Expenses		447,646			25,677			926,667			142,955
Net Income(Loss) from operations		(49,503	)		(24,040	)		(22,142	)		(110,657	)
Other (Expense)		(40,846	)		—			(143,551	)		—
Net (Loss) from Continuing Operations		(90,349	)		(24,040	)		(165,693	)		(110,657	)
Net Income from Discontinued Operations		—			—			1,081,173			—
Net Income (Loss)	$	(90,349	)	$	(24,040	)	$	915,480		$	(110,657	)
Basic and Diluted (Loss) Per Share:
Income(Loss) per share from Continuing Operations	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.00	)
Income(Loss) Per Share	$	(0.00	)	$	(0.00	)	$	0.00		$	(0.00	)
Weighted Average Shares Outstanding - Basic and Diluted		972,228,741			503,232,826			888,156,755			501,683,913

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

Omni Health, Inc.
and SUBSIDIARIES
Statements of Cash Flows
(unaudited)
For the Nine Months Ended January 31,

	2017			2016
Cash Flows From Operating Activities:
Net (Loss)		915,480		$	(110,657	)
Adjustments to Reconcile Net Loss to Net
Cash Provided By (Used In) Operating Activities:
Depreciation and Amortization		17,724			1,100
Common stock issued for services		—			57,104
Decrease (Increase) in:
Accounts Receivable, Net		(834,685	)		(25,215	)
Inventories		(259,512	)		7,624
Prepaid Expenses and Other Current Assets		(146,700	)		—
Accounts Payable, Accrued Expenses and Taxes Payable		293,706			(1,500	)
Deferred Revenue		—			(35,700	)
Total Adjustment to reconcile Net Income to Net Cash		(947,192	)		3,413
Net Cash Provided In Operating Activities		(13,988	)		(107,244	)
Cash Flows From Investing Activities:
Increase (Decrease) in:
Net cash received from acquisition		1,601			—
Net cash received in investing activities		1,601			—
Cash Flows From Financing Activities:
Proceeds (Reduction) from issuance of common stock		(954,215	)		—
Proceeds from long term loans		51,457
Proceeds from short term moans, Net		605,197			—
Proceeds (Repayments) to Related Party		(427,276	)		87,693
Net Cash Provided By (Used in) Financing Activities		(724,763	)		87,693
Net Change in Cash		(14,185	)		(19,551	)
Cash at Beginning of Period		21,834			70,516
Cash at End of Period	$	7,649		$	50,965

Supplemental Disclosure of Cash Flows Information:
Cash paid for interest	$	140,443		$	—
Cash paid for income taxes	$	—		$	—
Inventory transferred to related party	$	—		$	(2,460	)
Non-cash Investing and Financing Activities:
Net assets from Malecon Pharmacy Acquisition	$	3,392,500		$	—

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

OMNI HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Organization and Basis of Presentation

The accompanying audited financial statements of Omni Health, Inc., formerly known as VitaCig, Inc., (the “Company”, “we”, “our”), have been prepared in accordance with generally accepted accounting principles in the United States of America and the rules of the Securities and Exchange Commission (“SEC”).

Description of Business

We were incorporated in Nevada on January 22, 2014. We began as a technology company that was engaged in the manufacturing and retailing of nicotine-free Electronic Cigarettes (“eCigs”) that are pre-packaged with vitamins, nutrients, and generic pharmaceuticals.

The Company was originally formed as a wholly-owned subsidiary of mCig, Inc. On February 24, 2014 the company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement VitaCig, Inc. accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO and $500 in cash as contribution in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of the Company.

On November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc. (the “Spin-off”) (See Note 9: Stockholders’ Equity of the Audited Financial Statement).

On June 17, 2017 VitaCig acquired Malecon Pharmacy, Inc., in a Stock Exchange Agreement. VitaCig issued LX Retail Group, LLC 575,000,000 common shares of stock in exchange for 100% of the stock of Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., operates as a subsidiary of VitaCig, Inc. Malecon Pharmacy is a pharmacy that operates in Hialeah, Florida since 1974.

On June 22, 2017 VitaCig sold its eCig business element to mCig, Inc., in exchange for the return to treasury stock 172,500,000 shares of VitaCig stock and the reduction of the outstanding amount owed by Vitacig, Inc., to mCig, Inc., in the amount equal to reducing the outstanding balance to $95,000. As a result of this transaction, VitaCig, Inc., became a holding company in which it has one wholly owned subsidiary, Malecon Pharmacy, Inc.

On September 9, 2017 the company changed its name to Omni Health, Inc.

The Company currently maintains its corporate office in Haileah, Florida.

Note 2 – Summary of Significant Accounting Policies

The principal accounting policies are set out below, these policies have been consistently applied to the period presented, unless otherwise stated:

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include: sales returns and other allowances; allowance for doubtful accounts; valuation of inventory; valuation and recoverability of long-lived assets; property and equipment; contingencies; and income taxes.

Table of Contents

On a regular basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

Inventory

Prior to the acquisition of Malecon Pharmacy and the discontinued operations, inventory consisted of finished product, e-Cig products valued at the lower of cost and net realizable value under the first-in, first-out method of costing. Upon the acquisition of Malecon Pharmacy, the inventory consisted of prescription drugs, non-prescription drugs and retail merchandise. The Company continues to value its inventory at the lower of cost and net realizable value under the first-in, first-out method of costing.

Item	January 31, 2017		April 30, 2017
Prescription Drugs	$	125,908	$	—
Non-prescription Drugs		41,244		—
Retail Merchandise		119,001		—
Finished Goods		—		26,641
Total Inventory	$	286,153	$	26,641

Accounts Receivable

The Company’s accounts receivable is primarily from its contracts associated with healthcare insurance companies. Under various agreements, the Company maintains receivables with 17 companies with accounts ranging from 30-90 days. While the company attempts to collect on all outstanding balances owed, the financial statements do not account for any outstanding receivables beyond 90 days. All receivables beyond 90 days are written off as a drawn down from revenue. Should the company collect at a later date, which it intends to do, the Company reinstates the revenue during the quarter in which it is paid. Due to the nature of these funds, the Company expects these receivables to be fully collectible and therefore has not estimated an allowance for doubtful accounts for the period. The Company did not report any accounts receivable from any of its retail customers. The following table reflects the accounts receivables as of January 31, 2017.

	Amount
0-30 days	$	284,881
31-60 days		259,196
61-90 days		295,316
Total	$	839,392

Intangible assets

The Company’s intangible assets consist primarily of certain website development costs and are amortized over its estimated useful life of three years.

Revenue Recognition

Pharmacy Services. We sells prescription drugs directly through our mail service pharmacies, home delivery, and through our retail pharmacy. We recognize revenues from prescription drugs sold by our mail service and home delivery and the retail pharmacy through contracts where we are the principal using the gross method at the contract prices negotiated with our customers. Revenue from Pharmacy Services includes: (i) the portion of the price the customer pays directly to us, net of any volume-related or other discounts paid back to the customer, (ii) the portion of the price paid to us in a national retail pharmacy network through the customers insurance plan, and (iii) administrative payments from national retail pharmacy network contracts for incentives and initiatives.

Table of Contents

determinable and (iv) collectability is reasonably assured. The Company has established the following revenue recognition policies in accordance with SAB 104:

Revenues generated from prescription drugs sold by mail service pharmacies are recognized when the prescription is shipped. At the time of shipment, the Company has performed substantially all of its obligations under its customer contracts and does not experience a significant level of reshipments.

Revenues generated from prescription drugs sold through national retail pharmacy network and associated administrative fees are recognized at the point-of-sale, which is when the claim is adjudicated by the online claims processing system.

We determine whether we are the principal or agent for our national retail pharmacy network transactions using the indicators set forth in Emerging Issues Task Force (“EITF”) Issue No. 99-19, “Reporting Revenue Gross as a Principal versus Net as an Agent” on a contract by contract basis. In all of our current contracts, we have determined we are the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in establishing the price, changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications and (v) having credit risk. Responsibilities under our customer contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the physician prior to dispensing, suggesting clinically appropriate generic alternatives where appropriate and approving the prescription for dispensing. Although we do not have credit risk with respect to Retail Co-Payments, management believes that all of the other indicators of gross revenue reporting are present.

Retail Pharmacy Segment ~ We recognize revenue from the sale of merchandise (other than prescription drugs) at the time the merchandise is purchased by the retail customer. Revenue from the sale of prescription drugs is recognized at the time the prescription is filled, which is or approximates when the retail customer picks up the prescription. Customer returns are not material. Revenue generated from the performance of services is recognized at the time the services are performed.

Cost of Goods Sold

The Company recognizes the direct cost of purchasing product for sale, including freight-in and packaging, as cost of goods sold in the accompanying income statement.

Financial Instruments

The carrying amounts reflected in the balance sheets for cash and due to related parties approximate the respective fair values due to the short maturities of these items. The Company does not hold any investments that are available-for-sale.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1—Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2—Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Table of Contents

Level 3—Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

Income Taxes

Income taxes are accounted for under the assets and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.

Basic and Diluted Net Income (Loss) Per Share

The Company follows ASC Topic 260 to account for earnings (loss) per share. Basic earnings (loss) per share (“EPS”) calculations are determined by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the three months. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

There is no potential dilutive security as of January 31, 2017 or 2016.

Concentration of Credit Risk

Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash and trade receivables. Concentrations of credit risk with respect to trade receivables are limited due to the clients that comprise our customer base and their dispersion across different business and geographic areas. We estimate and maintain an allowance for potentially uncollectible accounts and such estimates have historically been within management's expectations.

Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States. The Company may occasionally maintain amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed by maintaining all deposits in high quality financial institutions. The Company had no deposits in excess of federally insured limits at January 31, 2017 and April 30, 2016.

Impairment of Long-lived Assets

The Company accounts for long-lived assets in accordance with the provisions of FASB Topic 360, “Accounting for the Impairment of Long-Lived Assets”. This statement requires that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when the estimated future cash flows from the use of the asset are less than the carrying amount of that asset. No impairments were recorded during the periods ended January 31, 2017 and 2016.

Warranties

Warranty reserves include management’s best estimate of the projected costs to repair or to replace any items under warranty, based on actual warranty experience as it becomes available and other known factors that may impact the Company’s evaluation of historical data. The Company did not have any significant warranty expenses to report for the three months ended January 31, 2017. Based on these actual expenses, the warranty reserve, as estimated by management as of January 31, 2017 was at $0. Any adjustments to warranty reserves are to be recorded in cost of sales.

Recent Accounting Pronouncements

The Company evaluated all recent accounting pronouncements issued and determined that the adoption of these pronouncements would not have a material effect on the financial position, results of operations, or cash flows of the Company.

~~Amortization~~Table expense on intangible assets was $258 and $0 for the six months and three months period ending October 31, 2016, respectively, and $1,466 for the year ended April 30, 2016. The intangible asset was sold as part of ~~the Company's discontinued operation on June 22, 2016. See Note 10. Note 5 - Notes Payable The following table lists the short term and long term notes payable:~~Contents

Short Term Notes Payable	Original Amount/Assumed Amount	As of October 31, 2016
Current portion of the Lending Club	10,070	10,866
Small Business loan	268,331	161,935
Current portion of Circle Back Lending	5,230	5,647
Star Capital Loan	1,000,000	646,110
Assumed Liabilities	20,532	6,750
Due to mCig	95,000	-
Loan from Shareholder	10,000	10,000
Total Short Term Notes Payable	1,409,163	841,308
Long Term Notes Payable
The Lending Club	23,376	18,518
Circle Back Lending	12,448	10,009
Loan from Shareholder	812,000	573,000
Total Long Term Notes Payable	847,824	601,527
Total Notes Payable	2,256,987	1,292,835

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Components of an Entity, which updates the definition of discontinued operations. Going forward, only those disposals of components of an entity that represent a strategic shift that has (or will have) a major effect on an entity's operations and financial results will be reported as discontinued operations in the financial statements. Previously, a component of an entity that is a reportable segment, an operating segment, a reporting unit, a subsidiary, or an asset group was eligible for discontinued operations presentation. Additionally, the condition that the entity not have any significant continuing involvement in the operations of the component after the disposal transaction has been removed. The effective date for the revised standard is for applicable transactions that occur within annual periods beginning on or after December 15, 2014. We do not expect the guidance to have a material impact on the Company.

AsIn July ~~a part of the discontinue operations of VitaCig the company entered into a convertible promissory note with mCig, Inc., in the amount of $95,000 on June 6,~~ 2016~~. The company accrued $3~~,~~108~~ ~~in interest on~~ the ~~promissory~~Financial ~~note~~Accounting ~~through~~Standards ~~October~~Board ~~31,~~(“FASB”) ~~2016~~issued ~~bringing~~ASU ~~the total balance due to $98,108~~No. ~~On October 31,~~ 2016-11 ~~mCig,~~"Simplifying ~~Inc. elected to convert~~ the ~~promissory note into shares~~ Measurement of ~~the~~Inventory"; ~~company's~~guidance ~~stock.~~which ~~See~~requires ~~Note~~inventory 8.within ~~The Lending Club loan was executed by Malecon Pharmacy on April 23, 2016 in~~ the ~~amount~~scope of ~~$35,000. The company assumed~~ the ~~remaining~~standard ~~balance of $33,446 on June 17, 2016. The note is scheduled~~ to be ~~paid~~measured ~~off~~at ~~on March 23, 2019 and has a monthly payment of $1,218. The Small Business loan was executed by Malecon Pharmacy on April 22, 2016 in~~ the ~~amount~~lower of ~~$300,000.~~cost ~~The~~and net ~~company~~realizable ~~assumed the remaining balance of $161,935 on June 17, 2016~~value. ~~The~~Previous ~~payment~~guidance ~~terms~~required ofinventory ~~the~~to ~~note~~be ~~are~~measured ~~$1,550 each business day for 240 business days. There was 209 business days left on the note~~ at the ~~time~~lower of ~~acquisition~~cost ~~and~~or ~~116~~market ~~remaining~~(where asmarket ~~of October 31, 2016. The Circle Back Lending loan~~ was ~~executed~~defined as byreplacement ~~Malecon Pharmacy on April 21~~cost, ~~2016~~with ina ~~the~~ceiling ~~amount~~ of ~~$18,500.~~net ~~The~~realizable ~~company~~value ~~assumed~~and ~~the~~floor ~~remaining balance~~ of ~~$17,718~~net onrealizable ~~June~~value ~~17,~~less ~~2016. The note is scheduled to be paid off on March 21, 2019 and has~~ a ~~monthly~~normal ~~payment~~profit ~~of $674~~margin). The updated ~~Star~~guidance ~~Capital~~is ~~loan~~effective ~~was~~for ~~executed~~interim byand ~~the~~annual ~~Malecon~~reporting ~~Pharmacy~~periods onbeginning ~~June~~after ~~24, 2016 in the amount of $500,000. The note is scheduled to be paid off on~~ December 2315, ~~2016 and has a monthly payment of $90~~2017,~~833.~~ ~~In September 2016, the company entered into a second loan~~ with ~~Star~~early ~~Capital~~adoption permitted. ~~for~~There upwere tovarious another ~~additional~~updates ~~$500,000~~recently ~~in financing. The company has received $350~~issued,~~000.~~ ~~The~~none ~~company recognizes the remaining amount~~ of ~~$150,000~~which asare ~~other~~expected ~~receivable. The company is scheduled~~ to ~~pay off this new loan portion on August 2017 and has~~ a ~~monthly~~have ~~payment of $49,167. The company assumed certain other liabilities and~~ a ~~loan~~material ~~from~~impact ~~the~~on ~~shareholder of Malecon Pharmacy in~~ the ~~amount~~Company’s financial ~~of $30~~position,~~532~~ ~~for~~results ~~various~~of ~~obligations associated with the day-to-day~~ operations ofor ~~the~~cash ~~specialty pharmacy~~flows. The company paid $5,243 during the period ending October 31, 2016 leaving a remaining balance of $6,750 in assumed liabilities and $10,000 due to related party. Note 6 - Related Parties and Related Party Transactions Details of balances between the company and related partied are disclosed below:

		As of October 31, 2016		As of April 30, 2016
Loan from related parties		$ 583,000		$ 96,208

Note 3. Going Concern

The Company's financial statements are prepared using generally accepted accounting principles, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. Because the business is new and has a limited history and relatively few sales, no certainty of continuation can be stated. The accompanying financial statements for the nine months and three months ended January 31, 2017 and 2016 have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has suffered losses from operations and has a working capital deficit, which raises substantial doubt about its ability to continue as a going concern.

Management is taking steps to raise additional funds to address its operating and financial cash requirements to continue operations in the next twelve months. Management has devoted a significant amount of time in the raising of capital from additional debt and equity financing. However, the Company’s ability to continue as a going concern is dependent upon raising additional funds through debt and equity financing and generating revenue. There are no assurances the Company will receive the necessary funding or generate revenue necessary to fund operations. The financial statements contain no adjustments for the outcome of this uncertainty.

Note 4. Intangible Assets:

		As of
		April 30, 2017
	Weighted Average Useful Life (in Years)	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
		$	$	$
Finite lived intangible assets
Internet website	3	4,400	(2,799)	1,601
Total identifiable intangible assets		4,400	(2,799)	1,601

			As of
			June 22, 2017

~~The~~Table following entities have been identified as related parties: LX Retail Group, Inc. Greater than 10% stockholder. Andrey Soloviev Director and CEO mCig, Inc. Greater than 10% stockholder during the reporting period. The Chief Financial Officer of mCig, Inc., is the current Interim CEO and Interim CFO of the Company. On June 22, 2016 when the company acquired Malecon Pharmacy, Inc., it assumed the liability of $812,000 owed to the principal owner of Malecon Pharmacy, Inc. During the three months and six months ended October 31, 2016, the company paid $77,000 and $239,000 towards that outstanding balance, respectively, leaving a balance of $573,000 owed. Note 7 - Commitments and Contingencies The Company has commitments for three leased facilities. In addition, the Company has a lease commitment for its pharmacy software system. - The company office and conference facilities located in Miami Beach, Florida. The office rent is $5,947.41 per month. The lease expires on May 1, 2019. - The Company Pharmacy building and headquarters are in Hialeah, Florida. The rent for the facility is $8,146.74 per month. The lease expires on February 1, 2017. - The Company Warehouse and Distribution Center in Miami Florida. The company pays $1,605 a month as rent, which expires August 1, 2017. - The Company has a lease for its QS/1 Data System. The company pays $527.26 per month, which expires on April 30, 2018. The following chart shows the Company commitments for the next five years:Contents

Year		Amount
	Weighted Average Useful Life (in Years)		Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
2016		$ 97,359
			$	$	$
2017		178,425
Finite lived intangible assets
2018		81,127
Internet website	3		4,400	(3,057)	1,343
2019		71,370
Total identifiable intangible assets			4,400	(3,057)	1,343
2020		5,948
Total		$ 434,229

~~Note~~Amortization expense 8on -intangible ~~Stockholders'~~assets ~~Equity~~was ~~(Deficit)~~$258 ~~Common~~and ~~Stock The authorized capital stock of the Company consists of 2,000,000,000 shares of Common Stock, par value~~ $0~~.0001~~ per share. On February 24, 2014, the Company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement, VitaCig, Inc. accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the ~~term~~nine ~~“VitaCig”~~months ~~filed~~and ~~with~~three ~~the~~months ~~USPTO~~period onending January 1831, ~~2014~~2017, respectively, and $500 in cash as contribution in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of the Company. On November 28, 2014, mCig completed the spin-off of 54.1~~% of VitaCig~~,466 ~~Inc.~~for (the “Spin-off). As of April 30, 2016, the Company was authorized to issue 560,000,000 common shares at a par value of $0.0001. As of April 30, 2015 the Company had issued 500,135,000 common shares. During the year ~~the~~ended ~~Company issued 54,416,683 shares of common stock for services rendered - the price evaluate is $441,405. As of~~ April 30, ~~2016 the total issued and outstanding of common stock was 554,551,683~~2017. On June 17, 2016, the Company issued LX Retailers, LLC 575,000,000 shares of the Company’s common stock as the purchase price for Malecon Pharmacy. On October 31, 2016 mCig elected to convert its promissory note into shares of the company stock. The ~~total~~intangible ~~amount~~asset ~~due at the time of conversion~~ was ~~$98,108.~~sold ~~The~~as ~~company~~part ~~issued 17,677,058. Note 9 - Acquisition~~ of ~~Malecon Pharmacy, Inc. On June 17, 2016,~~ the Company and LX Retail Group, Inc. entered into a share exchange agreement whereby the Company acquired 100% of the stock of Malecon Pharmacy, Inc., whereby LX Retail Group, Inc. transferred the assets and operations of the business of Malecon Pharmacy, Inc., to Company in exchange for 575,000,000 shares of the Company’s ~~Common~~discontinued ~~Stock.~~operation on ~~The~~June ~~purchase price of Malecon Pharmacy~~22, ~~Inc~~2017., ~~was~~See ~~$3,392,500.~~Note ~~The following table summarizes the estimated fair values of the assets acquired and the liabilities assumed, at the date of acquisition:~~10.

Purchase Price (575,000,000 shares @ $0.0059)	$	3,392,500
Cash	$	107,276
Accounts Receivable		739,224
Inventory		256,507
Medical Equipment		254,232
Property, plant & equipment		64,661
Cost basis investment		3,430,973
Total assets acquired	$	4,852,873
Accounts Payable		359,510
Other Liabilities		20,532
Small Business Loan		268,331
Due to Related Party		812,000
Total liabilities assumed		1,460,373
Net assets acquired	$	3,392,500

Note 5. Notes Payable

The following table lists the short term and long term notes payable:

Short Term Notes Payable	Original Amount/Assumed Amount	As of January 31, 2017
Current portion of the Lending Club	10,070	11,287
Small Business loan	268,331	82,371
Current portion of Circle Back Lending	5,230	5,914
Star Capital Loan	1,000,000	482,863
Assumed Assumed Liabilities	20,532	-
Due to mCig	95,000	-
Accounts Receivable Factoring	-	257,125
Loan from Shareholder	10,000	10,000
Total Short Term Notes Payable	1,409,163	849,560
Long Term Notes Payable
The Lending Club	23,376	15,534
Circle Back Lending	12,448	8,434
Loan from Shareholder	812,000	573,000
Total Long Term Notes Payable	847,824	596,968
Total Notes Payable	2,256,987	1,446,528

As a part of the discontinue operations of VitaCig the company entered into a convertible promissory note with mCig, Inc., in the amount of $95,000 on June 6, 2017. The company accrued $3,108 in interest on the promissory note through January 31, 2017 bringing the total balance due to $98,108. On January 31, 2017 mCig, Inc. elected to convert the promissory note into shares of the company’s stock. See Note 8.

The Lending Club loan was executed by Malecon Pharmacy on April 23, 2017 in the amount of $35,000. The company assumed the remaining balance of $33,446 on June 17, 2017. The note is scheduled to be paid off on March 23, 2019 and has a monthly payment of $1,218.

The Small Business loan was executed by Malecon Pharmacy on April 22, 2017 in the amount of $300,000. The company assumed the remaining balance of $161,935 on June 17, 2017. The payment terms of the note are $1,550 each business day for 240 business days. There was 209 business days left on the note at the time of acquisition and 116 remaining as of January 31, 2017.

Table of Contents

The Circle Back Lending loan was executed by Malecon Pharmacy on April 21, 2017 in the amount of $18,500. The company assumed the remaining balance of $17,718 on June 17, 2017. The note is scheduled to be paid off on March 21, 2019 and has a monthly payment of $674.

The Star Capital loan was executed by the Malecon Pharmacy on June 24, 2017 in the amount of $500,000. The note is scheduled to be paid off on December 23, 2017 and has a monthly payment of $90,833. In September 2017, the company entered into a second loan with Star Capital for up to an additional $500,000 in financing. The company has received $350,000. The company recognizes the remaining amount of $150,000 as other receivable. The company is scheduled to pay off this new loan portion on August 2017 and has a monthly payment of $49,167.

The company assumed certain other liabilities and a loan from the shareholder of Malecon Pharmacy in the amount of $30,532 for various obligations associated with the day-to-day operations of the specialty pharmacy. The company paid $5,243 during the period ending January 31, 2017 leaving a remaining balance of $6,750 in assumed liabilities and $10,000 due to related party.

Note 6. Related Parties and Related Party Transactions

Details of balances between the company and related partied are disclosed below:

	As of January 31, 2017				As of April 30, 2017
Loan from related parties	$	583,000			$	188,276

The following entities have been identified as related parties:

LX Retail Group, Inc. Greater than 10% stockholder.

Malecon Pharmacy, Inc. Subsidiary company.

Andrey Soloviev Director and CEO

On June 22, 2017 when the company acquired Malecon Pharmacy, Inc., it assumed the liability of $812,000 owed to the principal owner of Malecon Pharmacy, Inc. During the three months and nine months ended January 31, 2017, the company paid $77,000 and $239,000 towards that outstanding balance, respectively, leaving a balance of $573,000 owed.

Note 7. Commitments and Contingencies

The Company has commitments for three leased facilities. In addition, the Company has a lease commitment for its pharmacy software system.

The company headquarters located in Miami Beach, Florida. The office rent is $5,947.41 per month. The lease expires on May 1, 2019.

The Company Pharmacy building in Hialeah, Florida. The rent for the facility is $8,146.74 per month. The lease expires on February 1, 2017.

The Company Warehouse and Distribution Center in Miami Florida. The company pays $1,605 a month as rent, which expires August 1, 2017.

The Company has a lease for its QS/1 Data System. The company pays $527.26 per month, which expires on April 30, 2018.

The following chart shows the Company commitments for the next five years:


Year		Amount
2017	$	48,680

2018		178,425
2019		81,127
2020		71,370
2021		5,948
Total	$	387,131

Table of Contents

Note 8. Stockholders’ Equity (Deficit)

Common Stock

The authorized capital stock of the Company consists of 2,000,000,000 shares of Common Stock, par value $0.0001 per share.

On February 24, 2014, the Company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement, VitaCig, Inc. accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO on January 18, 2014, and $500 in cash as contribution in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of the Company.

On November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc. (the “Spin-off).

As of April 30, 2017, the Company was authorized to issue 560,000,000 common shares at a par value of $0.0001. As of April 30, 2016 the Company had issued 500,135,000 common shares. During the year the Company issued 54,416,683 shares of common stock for services rendered - the price evaluate is $441,405. As of April 30, 2017 the total issued and outstanding of common stock was 554,551,683.

On June 17, 2017, the Company issued LX Retailers, LLC 575,000,000 shares of the Company’s common stock as the purchase price for Malecon Pharmacy.

On January 31, 2017 mCig elected to convert its promissory note into shares of the company stock. The total amount due at the time of conversion was $98,108. The company issued 17,677,058.

Note 9. Acquisition of Malecon Pharmacy, Inc.

On June 17, 2017, the Company and LX Retailers, LLC entered into a share exchange agreement whereby the Company acquired 100% of the stock of Malecon Pharmacy, Inc., whereby LX Retailers, LLC transferred the assets and operations of the business of Malecon Pharmacy, Inc., to Company in exchange for 575,000,000 shares of the Company’s Common Stock.

The purchase price of Malecon Pharmacy, Inc., was $3,392,500. The following table summarizes the estimated fair values of the assets acquired and the liabilities assumed, at the date of acquisition:

Purchase Price (575,000,000 shares @ $0.0059)	$	3,392,500

Cash	$	107,276
Accounts Receivable		739,224
Inventory		256,507
Medical Equipment		254,232
Property, plant & equipment		64,661
Cost basis investment		3,430,973
Total assets acquired	$	4,852,873

Accounts Payable		359,510
Other Liabilities		20,532
Small Business Loan		268,331

Due to Related Party		812,000
Total liabilities assumed		1,460,373
Net assets acquired	$	3,392,500

Table of Contents

In accordance with ASC 805-10-50, the Company is providing the following unaudited pro-forma to present a summary of the combined results of the Company’s consolidated operations with the acquisition as if the acquisition had been completed as of the beginning of the reporting period.

For three month ending October 31,

For six months ending October 31,

For three month ending January 31,

For nine months ending January 31,

CONSOLIDATED STATEMENT of OPERATIONS:

~~2016~~2017

~~2015~~2016

~~2016~~2017

~~2015~~2016

Sales

1,~~285~~470,~~503~~844

1,503,330

24,~~912~~383,~~190~~034

34,~~300~~804,~~946~~276

Cost of Sales

~~904~~1,~~692~~072,701

1,170,735

12,~~690~~763,~~366~~067

23,~~609~~780,~~788~~523

Gross Profit

~~380~~398,~~811~~143

332,595

1,~~221~~619,~~824~~967

~~691~~1,~~158~~023,753

Operating Expenses

~~345~~447,~~344~~646

315,690

~~578~~1,~~463~~026,109

1,~~346~~662,~~766~~456

(Loss) from Operations

35(49,~~467~~503)

16,905

~~643~~593,~~361~~858

(~~655~~638,~~608~~703)

Other Income / (Expense)

(7340,~~772~~846)

(~~102~~143,~~705~~551)

Gain from discontinued operations

1,~~078~~081,~~457~~173

Net Income (Loss)

(3890,~~305~~349)

16,905

1,~~619~~531,~~113~~480

(~~655~~638,~~608~~703)

Note 10. - Discontinued Operations On June 22, 2016, the Company sold off its VitaCig operations. The Company was returned 172,500,000 shares of common stock of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from mCig, Inc., and was forgiven $68,123 in debt owed to MCIG in exchange for the VitaCig operations. The record date for the transaction was June 22, 2016. The transaction was completed for the purpose of legally and structurally separating the VitaCig operation from the newly acquired business and the Company’s change in direction. The selloff of VitaCig has been presented as discontinued operations in our financial statements. The following tables represent the current assets and liabilities associated with the discontinued operations as of October 31, 2016: Assets

On June 22, 2017, the Company sold off its VitaCig operations. The Company was returned 172,500,000 shares of common stock of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from mCig, Inc., and was forgiven $68,123 in debt owed to MCIG in exchange for the VitaCig operations. The record date for the transaction was June 22, 2017. The transaction was completed for the purpose of legally and structurally separating the VitaCig operation from the newly acquired business and the Company’s change in direction.

The selloff of VitaCig has been presented as discontinued operations in our financial statements. The following tables represent the current assets and liabilities associated with the discontinued operations as of January 31, 2017:

Assets

Cash	$	44,280
Accounts receivable		10,518
Prepaid expenses		3,300
Inventory		26,607
Intangible assets		1,343
Total assets related to discontinued operations	$	86,048

Liabilities

Current liabilities		12,974
Deferred revenue		31,874
Due to mCig payable		68,123
Due to related party		2,000
Liabilities related to discontinued operations	$	114,971

As of ~~October~~January 31, ~~2016~~2017, the Company has recorded a gain of $1,~~078~~081,~~457~~173 for its discontinued operations. The following table presents the net book value of VitaCig as of the selloff, the pro-rata value received as part of the selloff, and the net gain for the selloff of the VitaCig operations:

Net book value of VitaCig at selloff	$	(28,923)
FMV of stock received as purchase price		1,049,534
Net gain from selloff	$	1,078,457

Net book value of VitaCig at sell-off

(28,923)

Note 11. Basic Loss per Share Basic Income (Loss) Per Share - The computation of basic and diluted loss per common share is based on the weighted average number of shares outstanding during each period. 13

FMV of stock received from sell-off			1,052,250
Net gain from discontinued operations		$	1,081,173

	Three Months Ended
	October 31,
	2016	2015
Net income (loss)	$ (14,308)	$ (67,105)
Basic income (loss) per share	$ (0.00)	$ (0.00)
Basic weighted average number of shares outstanding	854,959,292	503,232,826

	Six Months Ended
	October 31,
	2016	2015
Net income (loss)	$ 1,013,824	$ (86,617)
Basic income (loss) per share	$ (0.00)	$ (0.00)
Basic weighted average number of shares outstanding	854,959,292	501,683,913

Table of Contents

~~The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during the periods.~~ Note 12 - Subsequent Events In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report 11. ~~Item~~Basic 2.Loss ~~Management’s~~per Discussion and Analysis of Financial Condition and Results of Operations Unless otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” are to the Company, unless the context requires otherwise. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed interim financial statements and the accompanying related notes included in this quarterly report and our audited financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended April 30, 2016 filed with the Securities and Exchange Commission. Cautionary Statement Regarding Forward-Looking Statements This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. 14Share

~~Additional~~Basic Income information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended April 30, 2016. Unless otherwise indicated or the context otherwise requires, all references in this Form 10-Q to “we,” “us,” “our,” “our company,” “Omni Health” or the “Company” refer to Omni Health, Inc. Our Ability to Continue as a Going Concern Our independent registered public accounting firm has issued its report dated October 31, 2016, in connection with the audit of our annual financial statements as of April 30, 2016, that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern and Note 3 to the unaudited financial statements for the period ended October 31, 2016 also describes the existence of conditions that raise substantial doubt about our ability to continue as a going concern. Overview Corporate History We were incorporated in Nevada on January 22, 2014. We began as a technology company that was engaged in the manufacturing and retailing of nicotine-free Electronic Cigarettes (~~“eCigs”~~Loss) ~~that~~Per ~~are pre~~Share -~~packaged~~ ~~with~~The ~~vitamins,~~computation ~~nutrients, and generic pharmaceuticals. We were originally formed as a wholly-owned subsidiary~~ of ~~mCig,~~basic Inc. On February 24, 2014, our company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement we accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO and ~~$500~~diluted inloss ~~cash~~per ~~as contribution in exchange for 500,135,000 shares of~~ common ~~capital~~share ~~stock~~is ~~representing~~based ~~100%~~on of the ~~shares~~weighted ~~outstanding~~average number of VitaCig, Inc. On November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc. On June 17, 2016 VitaCig acquired Malecon Pharmacy, Inc., in a Stock Exchange Agreement. VitaCig issued LX Retail Group, LLC 575,000,000 common shares of stock in exchange for 100% of the stock of Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., operates as a subsidiary of VitaCig, Inc. Malecon Pharmacy is a premiere anti-aging cream manufacturer, wholesaler, and distributor. On June 22, 2016 VitaCig sold its eCig business element to mCig, Inc., in exchange for the return to treasury stock 172,500,000 shares of VitaCig stock and the reduction of the outstanding ~~amount~~during ~~owed~~each ~~by Vitacig, Inc~~period., to mCig, Inc., the amount of $122,394. As a result of this transaction, VitaCig, Inc., became a holding company in which it has one wholly owned subsidiary, Malecon Pharmacy, Inc. On August 9, 2016 the Company changed its name from “VitaCig, Inc.” to “Omni Health, Inc.”. The fiscal year end is April 30. Our Company The Company operates a pharmacy in Hialeah, Florida. All of our operations are conducted through our wholly-owned subsidiaries, Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., is a vertically integrated company focused on healthcare and operating in the highly lucrative pharmaceutical, medical and wellness industries, since 1974. We are licensed provider of innovative health, wellness and pharmacy services through our pharmacy located in Hialeah, Florida. 15

Governmental Regulation Our business is subject to federal, state and local laws, regulations, and administrative practices, including, among others: federal, state and local licensure and registration requirements concerning the operation of pharmacies and the practice of pharmacy; the Health Insurance Portability and Accountability Act (HIPAA); the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2012 (collectively, the Health Reform Law); statutes and regulations of the FDA, the U.S. Federal Trade Commission, the U.S. Drug Enforcement Administration and the U.S. Consumer Product Safety Commission, as well as regulations promulgated by comparable state agencies concerning the sale, advertisement and promotion of the products we sell. Below are descriptions of some of the various federal and state laws and regulations which may govern or impact our current and planned operations. Pharmacy Regulation Our pharmacy operations are regulated by both individual states and the federal government. Every state has laws and regulations addressing pharmacy operations, including regulations relating specifically to compounding pharmacy operations. These regulations generally include licensing requirements for pharmacists, pharmacy technicians and pharmacies, as well as regulations related to compounding processes, safety protocols, purity, sterility, storage, controlled substances, recordkeeping and regular inspections, among other things. State rules and regulations are updated periodically, generally under the jurisdiction of individual state boards of pharmacy. Failure to comply with the state pharmacy regulations of a particular state could result in a pharmacy being prohibited from operating in that state, financial penalties and/or becoming subject to additional oversight from that state’s board of pharmacy. In addition, many states are considering imposing, or have already begun to impose, more stringent requirements on compounding pharmacies. If our pharmacy operations become subject to additional licensure requirements, are unable to maintain their required licenses or if states place burdensome restrictions or limitations on pharmacies, our ability to operate could be limited. Certain provisions of the FDCA govern the preparation, handling, storage, marketing and distribution of pharmaceutical products. The Drug Quality and Security Act of 2013 (DQSA) clarifies and strengthens the federal regulatory framework governing compounding pharmacies. Title 1 of the DQSA, the Compounding Quality Act, modifies provisions of the Section 503A of the FDCA that were found to be unconstitutional by the U.S. Supreme Court in 2002. In general, Section 503A provides that pharmacies are exempt from the provisions of the FDCA requiring compliance with cGMP, labeling with adequate directions for use and FDA approval prior to marketing if the pharmacy complies with certain other requirements. Among other things, to comply with Section 503A, a compounded drug must be compounded by a licensed pharmacist for an identified individual patient on the basis of a valid prescription. Pharmacies may only compound in limited quantities before receipt of a prescription for an individual patient and are subject to limitations on anticipatory compounding for distribution, which generally permit anticipatory compounding only based on historical prescription volumes. Confidentiality, Privacy and HIPAA Our pharmacy operations involve the receipt, use and disclosure of confidential medical, pharmacy and other health-related information. In addition, we use aggregated and blinded (anonymous) data for research and analysis purposes. The federal privacy regulations under HIPAA are designed to protect the medical information of a healthcare patient or health plan enrollee that could be used to identify the individual. Among other things, HIPAA limits certain uses and disclosures of protected health information and requires compliance with federal security regulations regarding the storage, utilization and transmission of and access to electronic protected health information. The requirements imposed by HIPAA are extensive. In addition, most states have enacted privacy and security laws that protect identifiable patient information that is not health-related. Further, several states have enacted more protective and comprehensive pharmacy-related privacy legislation that not only applies to patient records but also prohibits the transfer or use for commercial purposes of pharmacy data that identifies prescribers. These regulations impose substantial requirements on covered entities and their business associates regarding the storage, utilization and transmission of and access to personal health and non-health information. Many of these laws apply to our business. Medicare and Medicaid Reimbursement Medicare is a federally funded program that provides health insurance coverage for qualified persons age 65 or older and for some disabled persons with certain specific conditions. State-funded Medicaid programs provide medical benefits to groups of low-income and disabled individuals, some of whom may have inadequate or no medical insurance. Currently, most of our commercially available formulations are sold in cash transactions and our customers may choose to seek reimbursement opportunities from Medicare, Medicaid and other third parties to the extent that they exist. As part of our initiative, we work with third-party insurers, pharmacy benefit managers and buying groups to offer patient-specific customizable compounded formulations at accessible prices. We plan to continue to devote time and other resources to seek reimbursement and patient pay opportunities for these and other compounded formulations and we have hired pharmacy billers to process certain existing reimbursement opportunities for certain formulations. However, we may be unsuccessful in achieving these goals, as many third-party payors have imposed significant restrictions on reimbursement for compounded formulations in recent years. Moreover, third-party payors, including Medicare, are increasingly attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in some cases, to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling approval. Further, the Health Reform Law may have a considerable impact on the existing U.S. system for the delivery and financing of health care and could conceivable have a material effect on our business. As a result, reimbursement from Medicare, Medicaid and other third-party payors may never be available for any of our products or, if available, may not be sufficient to allow us to sell the products on a competitive basis and at desirable price points. To the extent we obtain third-party reimbursement for our compounded formulations, we may become subject to Medicare, Medicaid and other publicly financed health benefit plan regulations prohibiting kickbacks, beneficiary inducement and the submission of false claims. 16

	Three Months Ended
	January 31,
	2017			2016
Net income (loss)	$	(90,349	)	$	(24,040	)
Basic income (loss) per share	$	(0.00	)	$	(0.00	)
Basic weighted average number of shares outstanding		975,828,741			503,232,826

Critical Accounting Policies and Estimates Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates, including those related to uncollectible receivables, inventory valuation, deferred compensation and contingencies. We base our estimates on historical performance and on various other assumptions that we believe to be reasonable under the circumstances. These estimates allow us to make judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We believe the following accounting policies are our critical accounting policies because they are important to the portrayal of our financial condition and results of operations and they require critical management judgments and estimates about matters that may be uncertain. If actual results or events differ materially from those contemplated by us in making these estimates, our reported financial condition and results of operations for future periods could be materially affected. Pharmacy Services. We sells prescription drugs directly through our mail service pharmacies, home delivery, and through our retail pharmacy. We recognize revenues from prescription drugs sold by our mail service and home delivery and the retail pharmacy through contracts where we are the principal using the gross method at the contract prices negotiated with our customers. Revenue from Pharmacy Services includes: (i) the portion of the price the customer pays directly to us, net of any volume-related or other discounts paid back to the customer, (ii) the portion of the price paid to us in a national retail pharmacy network through the customers insurance plan, and (iii) administrative payments from national retail pharmacy network contracts for incentives and initiatives. SEC Staff Accounting Bulletin 104, “Revenue Recognition, corrected copy” ( “SAB 104”) provides the general criteria for the timing aspect of revenue recognition, including consideration of whether: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable and (iv) collectability is reasonably assured. The Company has established the following revenue recognition policies in accordance with SAB 104: · Revenues generated from prescription drugs sold by mail service pharmacies are recognized when the prescription is shipped. At the time of shipment, the Company has performed substantially all of its obligations under its customer contracts and does not experience a significant level of reshipments. · Revenues generated from prescription drugs sold through national retail pharmacy network and associated administrative fees are recognized at the point-of-sale, which is when the claim is adjudicated by the online claims processing system. We determine whether we are the principal or agent for our national retail pharmacy network transactions using the indicators set forth in Emerging Issues Task Force (“EITF”) Issue No. 99-19, “Reporting Revenue Gross as a Principal versus Net as an Agent” on a contract by contract basis. In all of our current contracts, we have determined we are the principal due to it: (i) being the primary obligor in the arrangement, (ii) having latitude in establishing the price, changing the product or performing part of the service, (iii) having discretion in supplier selection, (iv) having involvement in the determination of product or service specifications and (v) having credit risk. Responsibilities under our customer contracts typically include validating eligibility and coverage levels, communicating the prescription price and the co-payments due to the retail pharmacy, identifying possible adverse drug interactions for the pharmacist to address with the physician prior to dispensing, suggesting clinically appropriate generic alternatives where appropriate and approving the prescription for dispensing. Although we do not have credit risk with respect to Retail Co-Payments, management believes that all of the other indicators of gross revenue reporting are present. Drug Discounts ~ We deduct from our revenues any discounts paid to our customers as required by EITF No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor’s Products)” (“EITF 01-9”). Retail Pharmacy Segment ~ We recognize revenue from the sale of merchandise (other than prescription drugs) at the time the merchandise is purchased by the retail customer. Revenue from the sale of prescription drugs is recognized at the time the prescription is filled, which is or approximates when the retail customer picks up the prescription. Customer returns are not material. Revenue generated from the performance of services is recognized at the time the services are performed. Amounts billed or collected in excess of revenue recognized are recorded as deferred revenue. 17

	Nine Months Ended
	January 31,
	2017		2016
Net income (loss)	$	915,480	$	(110,657	)
Basic income (loss) per share	$	0.00	$	(0.00	)
Basic weighted average number of shares outstanding		888,232,826		501,683,913

The ~~Our~~computation operating results for the three months ended October 31, 2016 and 2015 are summarized as follows: For the Three Months Ended October 31, 2016 2015 Revenue $ 1,285,503 $ 11,707 Cost of ~~Goods~~basic ~~Sold 904,692 3,616 Gross~~income ~~Profit 380,811 8,091 Expenses 345,344 75,196 Net Income~~(~~Loss~~loss) ~~from~~per ~~operations 35,467 (67,105) For~~common ~~the~~share Six Months Ended October 31, 2016 2015 Revenue $ 1,799,950 $ 78,743 Cost of Goods Sold 1,293,568 48,082 Gross Profit 506,382 30,661 Expenses 495,021 117,278 Net Income(Loss) from operations 11,361 (86,617) Results of Operations Three Months Ended October 31, 2016 Compared to Three Months Ended October 31, 2015 Revenue Our revenue from operations for the three months ended October 31, 2016 was $1,285,503 compared to $11,707, an increase of $1,273,796, for the three months ended October 31, 2015. This increase is ~~primarily~~based ~~due to an increase in sales upon the acquisition of Malecon Pharmacy~~ on ~~June 22, 2016. Revenues consist primarily of results from~~ the ~~sales~~weighted ofaverage ~~prescription~~number ~~drugs, non-prescription drugs, and specialty products and related accessories. Cost~~ of ~~Goods~~shares ~~Sold Our~~outstanding ~~cost~~during ~~of goods sold for~~ the ~~three months ended October 31, 2016 was $904,692 compared to $3,616 for the three months ended October 31, 2015~~periods. This increase is primarily due to the increase in sales. Gross Profit Our gross profit for the three months ended October 31, 2016 was $380,811 compared to $8,091 for the three months ended October 31, 2015. The gross profit of $380,811 for the three months ended October 31, 2016 represents approximately 29.6% as a percentage of total revenue. The gross profit of $8,091 for the three months ended October 31, 2015 represents approximately 69.1% as a percentage of total revenue. This decrease in the gross profit percentage is primarily attributed to the pricing policies of the company’s new subsidiary, Malecon Pharmacy. Operating Expenses Our operating expenses increased by $270,148 to $345,344 for the three months ended October 31, 2016, from $75,196 for the three months ended October 31, 2015. The increase was primarily due to the increases in payroll of $69,874, consulting fees of $131,738, selling, general and administrative expenses of $75,000, and depreciation of $7,286, and a decrease in professional fees of $13,750. Our total operating expenses for the three months ended October 31, 2016 of $345,344 consisted of $136,079 of selling, general and administrative expenses, $69,874 in payroll expenses, $131,738 in consulting fees, and $7,653 in depreciation expenses. Our general and administrative expenses consist of rent, bank charges, telephone expenses, meals and entertainments, computer and internet expenses, postage and delivery, office supplies and other expenses. 18

Net Income Our net loss decreased by $28,800 to $38,305 for the three months ended October 31, 2016 compared to a net loss of $67,105 for the three months ending October 31, 2015. The decrease in net income compared to the prior period is primarily a result of the increase in operating expenses of $270,148 and the increase in gross profit of $372,720. Six Months Ended October 31, 2016 Compared to Six Months Ended October 31, 2015 Revenue Our revenue from operations for the six months ended October 31, 2016 was $1,799,950 compared to $78,743, an increase of $1,721,207, for the six months ended October 31, 2015. This increase is primarily due to an increase in sales upon the acquisition of Malecon Pharmacy on June 22, 2016. Revenues consist primarily of results from the sales of prescription drugs, non-prescription drugs, and specialty products and related accessories. Cost of Goods Sold Our cost of goods sold for the six months ended October 31, 2016 was $1,293,568 compared to $48,082 for the six months ended October 31, 2015. This increase is primarily due to the increase in sales. Gross Profit Our gross profit for the six months ended October 31, 2016 was $506,382 compared to $30,661 for the six months ended October 31, 2015. The gross profit of $506,382 for the six months ended October 31, 2016 represents approximately 28.1% as a percentage of total revenue. The gross profit of $30,661 for the six months ended October 31, 2015 represents approximately 38.9% as a percentage of total revenue. This decrease in the gross profit percentage is primarily attributed to the pricing policies of the company’s new subsidiary, Malecon Pharmacy. Operating Expenses Our operating expenses increased by $377,923 to $495,021 for the six months ended October 31, 2016, from $117,278 for the six months ended October 31, 2015. The increase was primarily due to the increase in selling, general and administrative expenses of $98,076, an increase in payroll of $114,752, an increase in consulting fees of $170,670, an increase in depreciation of $6,920, and a decrease in professional fees of $Note 12~~,675~~. ~~Our~~Subsequent total operating expenses for the six months ended October 31, 2016 of $495,021 consisted of $200,871 of selling, general and administrative expenses, $114,752 in payroll expenses, $1,075 in professional fees, $170,670 in consulting fees, and $7,653 in depreciation expenses. Our general and administrative expenses consist of salaries, bank charges, telephone expenses, meals and entertainments, computer and internet expenses, postage and delivery, office supplies and other expenses. Net Income Our net income increased by $1,076,446 to $989,829 for the six months ended October 31, 2016 compared to a net loss of $86,617 for the six months ending October 31, 2015. The increase in net income compared to the prior period is primarily a result of the increase in gain from discontinued operation of $1,081,173, the increase in operating expenses of $377,743 and the increase in gross profit of $475,721. 19Events

~~Liquidity~~In accordance and Capital Resources Introduction During the six months ended October 31, 2016 because of the acquisition of Malecon Pharmacy, we generated positive operating cash flows. The net cash provided by operating activities was $55,370, and our cash on hand as of October 31, 2016 was $21,858. Cash Requirements We had cash available of $21,858 as of October 31, 2016. Based on our revenues, cash on hand and current monthly burn rate, we believe that our operations are sufficient to fund operations through April 2017. Sources and Uses of Cash Operations We had net cash provided in operating activities of $55,370 for the six months ended October 31, 2016, as compared to cash used of $62,153 for the six months ended October 31, 2015. Net cash provided in operations consisted primarily of the net income of $989,829. Changes in assets and liabilities consisted of increases in inventory of $240,378, accounts receivable of $781,072, an increase in Other receivable of $146,700, and an increase in accounts payable of $240,378. Investments We had net cash used in investing activities of $3,748,265 for the six months ended October 31, 2016 and $0 in cash used in investing activities for the six months ended October 31, 2015. Financing We had net cash provided in financing activities of $3,692,919 for the six months ended October 31, 2016, as compared to net cash used of $4,996 for the six months ended October 31, 2015. Our financing activities consisted primary of cash proceeds from issuance of common stock of $2,438,359, cash proceeds from loan with ~~related~~ASC ~~parties of $394,724 and an increase of notes payable of $859,836. As part of the discontinued operations, the company purchased $1,052,250 of its company stock held in treasury. Off~~855-~~Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition~~10, ~~changes~~Company inmanagement ~~financial~~reviewed ~~condition,~~all ~~revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider~~ material. ~~Going~~events ~~Concern~~through ~~Our financial statements are prepared using generally accepted accounting principles, which contemplate~~ the ~~realization~~date of assets and liquidation of liabilities in the normal course of business. Because the business is relatively new and has a short history and relatively few sales, no certainty of continuation can be stated. The accompanying financial statements for the three months and six months ended October 31, 2016 and 2015 have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred losses from operations and has a working capital deficit, which raises substantial doubt about its ability to continue as a going concern. Item 3. Quantitative and Qualitative Disclosures about Market Risk We are a smaller reporting company and therefore, we are not required to provide information required by this ~~Item~~report ~~of Form 10-Q. Item 4. Controls~~ and ~~Procedures~~determined ~~Evaluation of Disclosure Controls and Procedures Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure~~ that there information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure controls and procedures are ~~also~~no ~~designed~~additional tomaterial ~~ensure~~subsequent ~~that~~events ~~such information is accumulated and communicated~~ to ~~management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures~~report. 20

We carried out an evaluation, under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of October 31, 2015. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. Based on the evaluation described above, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report because we did not document our Sarbanes-Oxley Act Section 404 internal controls and procedures. As funds become available to us, we expect to implement additional measures to improve disclosure controls and procedures such as implementing and documenting our internal controls procedures. Changes in internal controls over financial reporting There have been no changes in our internal control over financial reporting during the quarter ended October 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Limitations on the Effectiveness of Controls A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The Company’s management, including its Principal Executive Officer and its Principal Financial Officer, do not expect that the Company’s disclosure controls will prevent or detect all errors and all fraud. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. PART II – OTHER INFORMATION Item 1. Legal Proceedings From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. Except as set forth below we are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results. Item 1A. Risk Factors As a smaller reporting company, we are not required to provide the information required by this Item. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds In the three months ended October 31, 2016, we have not issued any shares of stock. Item 3. Defaults Upon Senior Securities There have been no events that are required to be reported under this Item. Item 4. Mine Safety Disclosures There have been no events that are required to be reported under this Item. Item 5. Other Information There have been no events that are required to be reported under this Item. Item 6. Exhibits16

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless otherwise indicated, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” are to the Company, unless the context requires otherwise. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed interim financial statements and the accompanying related notes included in this quarterly report and our audited financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended April 30, 2017 filed with the Securities and Exchange Commission.

Cautionary Statement Regarding Forward-Looking Statements

This report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we intend that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Any such forward-looking statements would be contained principally in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities and the effects of regulation. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this report and the documents that we reference in this report and have filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Additional information concerning these and other risks and uncertainties is contained in our filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended April 30, 2017.

Unless otherwise indicated or the context otherwise requires, all references in this Form 10-Q to “we,” “us,” “our,” “our company,” “VitaCig” or the “Company” refer to VitaCig, Inc.

Table of Contents

Our Ability to Continue as a Going Concern

Our independent registered public accounting firm has issued its report dated January 31, 2017, in connection with the audit of our annual financial statements as of April 30, 2017, that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern and Note 3 to the unaudited financial statements for the period ended January 31, 2017 also describes the existence of conditions that raise substantial doubt about our ability to continue as a going concern.

Overview

Corporate History

We were originally formed as a wholly-owned subsidiary of mCig, Inc. On February 24, 2014, our company entered into a Contribution Agreement with mCig, Inc. In accordance with this agreement we accepted the contribution by mCig, Inc. of specific assets consisting solely of pending trademarks for the term “VitaCig” filed with the USPTO and $500 in cash as contribution in exchange for 500,135,000 shares of common capital stock representing 100% of the shares outstanding of VitaCig, Inc.

On November 28, 2014, mCig completed the spin-off of 54.1% of VitaCig, Inc.

On June 17, 2017 VitaCig acquired Malecon Pharmacy, Inc., in a Stock Exchange Agreement. VitaCig issued LX Retail Group, LLC 575,000,000 common shares of stock in exchange for 100% of the stock of Malecon Pharmacy, Inc. Malecon Pharmacy, Inc., operates as a subsidiary of VitaCig, Inc. Malecon Pharmacy is a premiere anti-aging cream manufacturer, wholesaler, and distributor.

On June 22, 2017 VitaCig sold its eCig business element to mCig, Inc., in exchange for the return to treasury stock 172,500,000 shares of VitaCig stock and the reduction of the outstanding amount owed by Vitacig, Inc., to mCig, Inc., the amount of $122,394. As a result of this transaction, VitaCig, Inc., became a holding company in which it has one wholly owned subsidiary, Malecon Pharmacy, Inc.

On August 9, 2017 the Company changed its name from “VitaCig, Inc.” to “Omni Health, Inc.”.

The fiscal year end is April 30.

Table of Contents

Our Company

The Company operates a pharmacy in Hialeah, Florida. All of our operations are conducted through our wholly-owned subsidiaries, Malecon Pharmacy, Inc.

Malecon Pharmacy, Inc., is a vertically integrated company focused on healthcare and operating in the highly lucrative pharmaceutical, medical and wellness industries, since 1974. We are licensed provider of innovative health, wellness and pharmacy services through our pharmacy located in Hialeah, Florida.

Governmental Regulation

Our business is subject to federal, state and local laws, regulations, and administrative practices, including, among others: federal, state and local licensure and registration requirements concerning the operation of pharmacies and the practice of pharmacy; the Health Insurance Portability and Accountability Act (HIPAA); the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2012 (collectively, the Health Reform Law); statutes and regulations of the FDA, the U.S. Federal Trade Commission, the U.S. Drug Enforcement Administration and the U.S. Consumer Product Safety Commission, as well as regulations promulgated by comparable state agencies concerning the sale, advertisement and promotion of the products we sell. Below are descriptions of some of the various federal and state laws and regulations which may govern or impact our current and planned operations.

Pharmacy Regulation

Our pharmacy operations are regulated by both individual states and the federal government. Every state has laws and regulations addressing pharmacy operations, including regulations relating specifically to compounding pharmacy operations. These regulations generally include licensing requirements for pharmacists, pharmacy technicians and pharmacies, as well as regulations related to compounding processes, safety protocols, purity, sterility, storage, controlled substances, recordkeeping and regular inspections, among other things. State rules and regulations are updated periodically, generally under the jurisdiction of individual state boards of pharmacy. Failure to comply with the state pharmacy regulations of a particular state could result in a pharmacy being prohibited from operating in that state, financial penalties and/or becoming subject to additional oversight from that state’s board of pharmacy. In addition, many states are considering imposing, or have already begun to impose, more stringent requirements on compounding pharmacies. If our pharmacy operations become subject to additional licensure requirements, are unable to maintain their required licenses or if states place burdensome restrictions or limitations on pharmacies, our ability to operate could be limited.

Certain provisions of the FDCA govern the preparation, handling, storage, marketing and distribution of pharmaceutical products. The Drug Quality and Security Act of 2013 (DQSA) clarifies and strengthens the federal regulatory framework governing compounding pharmacies. Title 1 of the DQSA, the Compounding Quality Act, modifies provisions of the Section 503A of the FDCA that were found to be unconstitutional by the U.S. Supreme Court in 2002. In general, Section 503A provides that pharmacies are exempt from the provisions of the FDCA requiring compliance with cGMP, labeling with adequate directions for use and FDA approval prior to marketing if the pharmacy complies with certain other requirements. Among other things, to comply with Section 503A, a compounded drug must be compounded by a licensed pharmacist for an identified individual patient on the basis of a valid prescription. Pharmacies may only compound in limited quantities before receipt of a prescription for an individual patient and are subject to limitations on anticipatory compounding for distribution, which generally permit anticipatory compounding only based on historical prescription volumes.

Confidentiality, Privacy and HIPAA

Our pharmacy operations involve the receipt, use and disclosure of confidential medical, pharmacy and other health-related information. In addition, we use aggregated and blinded (anonymous) data for research and analysis purposes. The federal privacy regulations under HIPAA are designed to protect the medical information of a healthcare patient or health plan enrollee that could be used to identify the individual. Among other things, HIPAA limits certain uses and disclosures

Table of Contents

of protected health information and requires compliance with federal security regulations regarding the storage, utilization and transmission of and access to electronic protected health information. The requirements imposed by HIPAA are extensive. In addition, most states have enacted privacy and security laws that protect identifiable patient information that is not health-related. Further, several states have enacted more protective and comprehensive pharmacy-related privacy legislation that not only applies to patient records but also prohibits the transfer or use for commercial purposes of pharmacy data that identifies prescribers. These regulations impose substantial requirements on covered entities and their business associates regarding the storage, utilization and transmission of and access to personal health and non-health information. Many of these laws apply to our business.

Medicare and Medicaid Reimbursement

Medicare is a federally funded program that provides health insurance coverage for qualified persons age 65 or older and for some disabled persons with certain specific conditions. State-funded Medicaid programs provide medical benefits to groups of low-income and disabled individuals, some of whom may have inadequate or no medical insurance. Currently, most of our commercially available formulations are sold in cash transactions and our customers may choose to seek reimbursement opportunities from Medicare, Medicaid and other third parties to the extent that they exist. As part of our initiative, we work with third-party insurers, pharmacy benefit managers and buying groups to offer patient-specific customizable compounded formulations at accessible prices. We plan to continue to devote time and other resources to seek reimbursement and patient pay opportunities for these and other compounded formulations and we have hired pharmacy billers to process certain existing reimbursement opportunities for certain formulations. However, we may be unsuccessful in achieving these goals, as many third-party payors have imposed significant restrictions on reimbursement for compounded formulations in recent years. Moreover, third-party payors, including Medicare, are increasingly attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in some cases, to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling approval. Further, the Health Reform Law may have a considerable impact on the existing U.S. system for the delivery and financing of health care and could conceivable have a material effect on our business. As a result, reimbursement from Medicare, Medicaid and other third-party payors may never be available for any of our products or, if available, may not be sufficient to allow us to sell the products on a competitive basis and at desirable price points.

To the extent we obtain third-party reimbursement for our compounded formulations, we may become subject to Medicare, Medicaid and other publicly financed health benefit plan regulations prohibiting kickbacks, beneficiary inducement and the submission of false claims.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates, including those related to uncollectible receivables, inventory valuation, deferred compensation and contingencies.

We base our estimates on historical performance and on various other assumptions that we believe to be reasonable under the circumstances. These estimates allow us to make judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

We believe the following accounting policies are our critical accounting policies because they are important to the portrayal of our financial condition and results of operations and they require critical management judgments and estimates about matters that may be uncertain. If actual results or events differ materially from those contemplated by us in making these estimates, our reported financial condition and results of operations for future periods could be materially affected.

Table of Contents

our customers. Revenue from Pharmacy Services includes: (i) the portion of the price the customer pays directly to us, net of any volume-related or other discounts paid back to the customer, (ii) the portion of the price paid to us in a national retail pharmacy network through the customers insurance plan, and (iii) administrative payments from national retail pharmacy network contracts for incentives and initiatives.

SEC Staff Accounting Bulletin 104, “Revenue Recognition, corrected copy” ( “SAB 104”) provides the general criteria for the timing aspect of revenue recognition, including consideration of whether: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable and (iv) collectability is reasonably assured. The Company has established the following revenue recognition policies in accordance with SAB 104:

Amounts billed or collected in excess of revenue recognized are recorded as deferred revenue.

Results of Operations

Our operating results for the three months and nine months ended January 31, 2017 and 2016 are summarized as follows:

	For the Three Months Ended January 31,
	2017		2016
Revenue	$	1,470,844	$	39,110
Cost of Goods Sold		1,072,701		37,473
Gross Profit		398,143		1,637
Expenses		447,646		25,677
Net Income(Loss) from operations		(49,503)		(24,040)

Table of Contents

	For the Nine Months Ended January 31,
	2017		2016
Revenue	$	3,270,793	$	117,853
Cost of Goods Sold		2,366,269		85,555
Gross Profit		904,524		32,298
Expenses		926,667		142,955
Net Income(Loss) from operations		(22,142)		(110,657)

Three Months Ended January 31, 2017 Compared to Three Months Ended January 31, 2016

Revenue

Our revenue from operations for the three months ended January 31, 2017 was $1,470,844 compared to $39,110, an increase of $1,431,734, for the three months ended January 31, 2016. This increase is primarily due to an increase in sales upon the acquisition of Malecon Pharmacy on June 22, 2017. Revenues consist primarily of results from the sales of prescription drugs, non-prescription drugs, and specialty products and related accessories.

Cost of Goods Sold

Our cost of goods sold for the three months ended January 31, 2017 was $1,072,701 compared to $37,473 for the three months ended January 31, 2016. This increase is primarily due to the increase in sales.

Gross Profit

Our gross profit for the three months ended January 31, 2017 was $395,143 compared to $1,637 for the three months ended January 31, 2016. The gross profit of $395,143 for the three months ended January 31, 2017 represents approximately 27.1% as a percentage of total revenue. The gross profit of $1,637 for the three months ended January 31, 2016 represents approximately 4.2% as a percentage of total revenue. This increase in the gross profit percentage is primarily attributed to the pricing policies of the company’s new subsidiary, Malecon Pharmacy.

Operating Expenses

Our operating expenses increased by $783,711 to $926,666 for the nine months ended January 31, 2017, from $142,955 for the nine months ended January 31, 2016. The increase was primarily due to the increase in selling, general and administrative expenses of $152,738, an increase in payroll of $187,080, an increase in consulting fees of $424,945, an increase in depreciation of $16,624, and in professional fees of $2,325.

Our total operating expenses for the nine months ended January 31, 2017 of $926,667 consisted of $275,843 of selling, general and administrative expenses, $187,080 in payroll expenses, $21,075 in professional fees, $424,945 in consulting fees, and $17,724 in depreciation expenses. Our general and administrative expenses consist of salaries, bank charges, telephone expenses, meals and entertainments, computer and internet expenses, postage and delivery, office supplies and other expenses.

Net Income

Our net loss increased by $25,463 to $49,503 for the three months ended January 31, 2017 compared to a net loss of $24,040 for the three months ending January 31, 2016. The decrease in net income compared to the prior period is primarily a result of the increase in operating expenses of $421,646 and the increase in gross profit of $393,506.

Table of Contents

Nine Months Ended January 31, 2017 Compared to Nine Months Ended January 31, 2016

Revenue

Our revenue from operations for the nine months ended January 31, 2017 was $3,270,793 compared to $117,853, an increase of $3,152,940, for the nine months ended January 31, 2016. This increase is primarily due to an increase in sales upon the acquisition of Malecon Pharmacy on June 22, 2017. Revenues consist primarily of results from the sales of prescription drugs, non-prescription drugs, and specialty products and related accessories.

Cost of Goods Sold

Our cost of goods sold for the nine months ended January 31, 2017 was $2,366,269 compared to $85,555 for the nine months ended January 31, 2016. This increase is primarily due to the increase in sales.

Gross Profit

Our gross profit for the nine months ended January 31, 2017 was $904,524 compared to $32,298 for the nine months ended January 31, 2016. The gross profit of $904,524 for the nine months ended January 31, 2017 represents approximately 27.7% as a percentage of total revenue. The gross profit of $32,298 for the nine months ended January 31, 2016 represents approximately 27.4% as a percentage of total revenue. This increase in the gross profit percentage is primarily attributed to the pricing policies of the company’s new subsidiary, Malecon Pharmacy.

Operating Expenses

Our operating expenses increased by $783,711 to $926,666 for the nine months ended January 31, 2017, from $142,955 for the nine months ended January 31, 2016. The increase was primarily due to the increase in selling, general and administrative expenses of $110,375, an increase in payroll of $261,111, an increase in consulting fees of $371,988, an increase in depreciation of $16,624, and in professional fees of $23,613.

Our total operating expenses for the nine months ended January 31, 2017 of $926,666 consisted of $233,480 of selling, general and administrative expenses, $261,111 in payroll expenses, $42,363 in professional fees, $371,988 in consulting fees, and $17,724 in depreciation expenses. Our general and administrative expenses consist of salaries, bank charges, telephone expenses, meals and entertainments, computer and internet expenses, postage and delivery, office supplies and other expenses.

Net Income

Our net income increased by $1,026,137 to $915,480 for the nine months ended January 31, 2017 compared to a net loss of $110,657 for the nine months ending January 31, 2016. The increase in net income compared to the prior period is primarily a result of the increase in gain from discontinued operation of $1,081,173, the increase in operating expenses of $783,711, an increase in interest expense of $143,551, and the increase in gross profit of $872,226.

Liquidity and Capital Resources

Introduction

During the nine months ended January 31, 2017 because of the acquisition of Malecon Pharmacy, we generated positive operating cash flows. The net cash provided by operating activities was $601,701, and our cash and cash equivalents on hand as of January 31, 2017 was $7,649.

Cash Requirements

We had cash available of $7,649 as of January 31, 2017. Based on our revenues, cash on hand and current monthly burn rate, we believe that our operations are sufficient to fund operations through April 2017.

Table of Contents

Sources and Uses of Cash

Operations

We had net cash provided in operating activities of $601,701 for the nine months ended January 31, 2017, as compared to cash used of $107,244 for the nine months ended January 31, 2016.

Net cash provided in operations consisted primarily of the net income of $915,480. Changes in assets and liabilities consisted of decreases in inventory of $3,006, accounts receivable of $95,460, an increase in other receivable of $146,700, and an increase in accounts payable of $86,336.

Investments

We had net cash received in investing activities of $1,601 for the nine months ended January 31, 2017 and $0 in cash used in investing activities for the nine months ended January 31, 2016.

Financing

We had net cash used in financing activities of $724,763 for the nine months ended January 31, 2017, as compared to net cash provided of $87,693 for the nine months ended January 31, 2016. Our financing activities consisted primary of cash provided from issuance of common stock of $98,109, cash used for loans with related parties of $427,276 and an increase of notes payable of $656,744 (which consisted on $51,457 in long term loans and $605,197 in short term loans). As part of the discontinued operations, the company purchased $1,052,250 of its company stock held in treasury.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.

Going Concern

Our financial statements are prepared using generally accepted accounting principles, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. Because the business is relatively new and has a short history and relatively few sales, no certainty of continuation can be stated. The accompanying financial statements for the three months and nine months ended January 31, 2017 and 2016 have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has incurred losses from operations and has a working capital deficit, which raises substantial doubt about its ability to continue as a going concern

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company and therefore, we are not required to provide information required by this Item of Form 10-Q.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures.

Table of Contents

As funds become available to us, we expect to implement additional measures to improve disclosure controls and procedures such as implementing and documenting our internal controls procedures.

Changes in internal controls over financial reporting

There have been no changes in our internal control over financial reporting during the quarter ended January 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The Company’s management, including its Principal Executive Officer and its Principal Financial Officer, do not expect that the Company’s disclosure controls will prevent or detect all errors and all fraud. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with associated policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. Except as set forth below we are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

Item 1A. Risk Factors

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In the three months ended January 31, 2017, we have not issued any shares of stock.

Table of Contents

Item 3. Defaults Upon Senior Securities

There have been no events that are required to be reported under this Item.

Item 4. Mine Safety Disclosures

There have been no events that are required to be reported under this Item.

Item 5. Other Information

There have been no events that are required to be reported under this Item.

Item 6. Exhibits

31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 *	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 *	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
		* Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Omni Health, Inc.
Dated: February 1, 2017		/s/ Andrey Soloviev
Dated: March 24, 2017		/s/ Andrey Soloviev
	By:	Andrey Soloviev
	Its:	Chief Executive Officer (Principal Executive Officer)

Dated: February 1, 2017		/s/ Michael W. Hawkins
Dated: March 24, 2017		/s/ Michael W. Hawkins
	By:	Michael W. Hawkins
	Its:	Chief Financial Officer (Principal Financial Officer)

2227

Filing Compare · OMNI HEALTH, INC.